Pnc Financial Services Group, Inc. I Mab Transaction History

Pnc Financial Services Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $6,053 - $13,490	-732 Reduced 86.52%	114 $1,000
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $5,316 - $19,898	424 Added 100.47%	846 $13,000
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $10,640 - $17,507	-235 Reduced 35.77%	422 $19,000
Q3 2021 Nov 05, 2021	BUY	$57.18 - $84.43 $28,246 - $41,708	494 Added 303.07%	657 $47,000
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $7,801 - $13,683	163 New	163 $13,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.